Clinical utility and safety of MultiHance® in magnetic resonance imaging of liver cancer: Results of multicenter studies in Europe and the USA

Journal of Computer Assisted Tomography

Volumn 23, Issue SUPPL., 1999, Pages

  Hamm, Bernd ^a   Kirchin, Miles ^b   Pirovano, Gianpaolo ^b   Spinazzi, Alberto ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Bracco SpA   (Italy)

Author keywords

Focal liver lesions; Gadobenate dimeglumine; Gd BOPTA; MR imaging

Indexed keywords

MAGNETISM; RESONANCE;

CLINICAL UTILITY; CONTRAST AGENT; FOCAL LIVER LESIONS; GADOBENATE DIMEGLUMINE; GADOLINIA; GD-BOPTA; LIVER CANCERS; MR IMAGING; MULTI-CENTRE STUDY; PROPERTY;

MAGNETIC RESONANCE IMAGING;

GADOBENATE DIMEGLUMINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG SAFETY; EUROPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMAGE QUALITY; LIVER CANCER; NAUSEA; NUCLEAR MAGNETIC RESONANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; UNITED STATES;

EID: 0033402017     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911001-00008     Document Type: Conference Paper

References (26)

1. Heiken JP, Weyman PJ, Lee JKT, et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography and MR imaging. Radiology 1989;171:47-51.
2. Stark DD, Wittenberg J, Butch RJ, Ferrucci JT. Hepatic metastases: randomized, controlled comparison of detection with MR imaging and CT. Radiology 1987;165:399-406.
3. Wernecke K, Rummeny E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. AJR 1991;157:731-9.
4. Karhunen PJ. Benign hepatic tumors and tumor-like conditions in men. J Clin Pathol 1986;39:183-8.
5. De Franco A, Monteforte MG, Maresca G, De Gaetano AM, Manfredi R, Marano P. Integrated diagnosis of liver angioma: comparison of Doppler color ultrasonography, computerized tomography and magnetic resonance. Radiol Med 1997;93:87-94.
6. Van Beers B, Demeure R, Pringot J, et al. Dynamic spin echo imaging with Gd-DTPA: value in the differentiation of hepatic tumors. AJR 1990:154:515-519.
7. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterisation with nonenhanced and dynamic contrast-material-enhanced MR imaging. Radiology 1994;190:417-23.
8. Ohtomo K, Itai Y, Yoshikawa K, et al. Hepatic tumors: dynamic MR imaging. Radiology 1987;163:27-31.
9. Hamm B, Fischer E, Taupitz M. Differentiation of hepatic hemangiomas from metastases by dynamic contrast-enhanced MR imaging. J Comput Assist Tomogr 1990;14:205-16.
10. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993;186:133-8.
11. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994;190:49-52.
12. Peterson MS, Baron RL, Murakami T. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201:337-345.
13. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-82.
14. Kirchin M, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809.
15. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-91.
16. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5:S86-9.
17. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. JMRI 1993;3:179-86.
18. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: Preliminary Evaluation in Healthy Volunteers. AJR 1992;157:887-92.
19. Giovagnoni A, Paci E. Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). MRI clinics of North America 1996;4:61-72.
20. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29: S183-5.
21. Caudana R, Morana G, Pirovano G, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1997;203:513-20.
22. Peterstein J, Spinazzi A, Giovagnoni A, et al. Evaluation of the efficacy of gadobenate dimeglumine in magnetic resonance imaging of focal liver lesions: a multicenter phase III clinical study. Radiology 2000 In press
23. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-8.
24. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. JMRI 1998;8:862-7.
25. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). JMRI 1999;9:704-10.
26. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma (HCC): correlation between gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging and pathological findings. Invest Radiol. 2000 In press.